(Q40826503)

24 September 2017

Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience (English)

1 reference

24 September 2017

1

1 reference

24 September 2017

Vidal R

2

1 reference

24 September 2017

Barros-Tizón JC

3

1 reference

24 September 2017

Bustamante A

4

1 reference

24 September 2017

España PP

5

1 reference

24 September 2017

Casas F

6

1 reference

24 September 2017

Martínez MT

7

1 reference

24 September 2017

Escudero C

8

1 reference

24 September 2017

Jardi R

9

1 reference

24 September 2017

1 October 1998

1 reference

24 September 2017

1 reference

24 September 2017

92

1 reference

24 September 2017

1181-1187

1 reference

24 September 2017

10

1 reference

Population Genetics of Alpha-1-Antitrypsin Polymorphism in US Whites, US Blacks and African Blacks

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

PI(alpha 1-antitrypsin) polymorphism in the Japanese: confirmation of PI*M4 and description of new PI variants

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Alpha 1-antitrypsin phenotypes in Northern Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Distribution of alpha-1-antitrypsin (Pi) phenotypes in Denmark determined by separator isoelectric focusing in agarose gel.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Design of a Clinical Trial to Test a Treatment of the Underlying Cause of Emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

[A report on the Spanish Registry of Patients with Alpha 1-Antitrypsin Deficiency. The Alpha 1-Antitrypsin Deficiency Study Group]

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Serum Pi types in some European, American, Asian and African populations

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

[Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency]

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Alpha 1-proteinase inhibitor (human) shortage

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Smoking, lung function, and alpha 1-antitrypsin deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

Serial measurements of FEV1 over 12 years in a patient with alpha-1-protease inhibitor deficiency:influence of augmentation therapy and infections

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2898%2990418-8

7 January 2021

10.1016/S0954-6111(98)90418-8

Identifiers

DOI

1 reference

24 September 2017

1 reference